Associated Papers
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E et al.
Genome Medicine, 2022
Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma.
Choi SW et al.
Cell Death & Disease, 2021
Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
Lee YJ et al.
Yonsei Medical Journal, 2019
Racial Disparities in the Molecular Landscape of Cancer.
Heath EI et al.
Anticancer Research, 2018
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Chen HH et al.
The Journal of Allergy and Clinical Immunology, 2017
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.
Chae YK et al.
Oncotarget, 2016
Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S et al.
Oncotarget, 2016
Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.
Xiu J et al.
Oncotarget, 2016
Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.
Pilarski R et al.
Journal of Medical Genetics, 2011
Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity.
Laury AR et al.
Thyroid : Official Journal of the American Thyroid Association, 2011
Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G et al.
Lung Cancer (amsterdam, Netherlands), 2010
The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management.
Tan WH et al.
Journal of Medical Genetics, 2007
Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma.
Nasrallah MP et al.
Academic Pathology, 0